Received Jun 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 5G23D | — |
| IPV | POLIO VIRUS, INACT. (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
Under age use; the RMA also gave a separated IPV-Polio vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 9-month-old male patient who received DTPa-IPV (Kinrix) suspension for injection in pre-filled syringe (batch number 5G23D with expiry date 21-AUG-2026) for prophylaxis. Co-suspect products included Polio vaccine inact (Ipv) for prophylaxis. Previously administered products included Dtap (received 2 doses on an unknown date). On 09-JUN-2026, the patient received the 3rd dose of Kinrix and Ipv. On 09-JUN-2026, an unknown time after receiving Kinrix and an unknown time after receiving Ipv, the patient experienced inappropriate age at vaccine administration (Verbatim: Under age use) and overdose (Verbatim: the RMA also gave a separated IPV-Polio vaccine). The outcome of the inappropriate age at vaccine administration and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-JUN-2026 The health care professional reported that they administered 1 dose of Kinrix to a 9 months old patient. The administration was done on the day of reporting and the reporter also gave a separated IPV-Polio vaccine. The reporter was ask what would be the adverse events of this situation for the patient, how would be the dosing schedule, the patient had prior doses of DTaP in 2 different combinations. The batch number was not provided upon follow up with the reporter.